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maceutical form. As the medication is mostly a long-term
regimen these resource uses were valued using biggest available
packages. Prices were taken from the German “Rote Liste” with
2006 as price year. In addition, cost-inﬂuencing factors were
analysed via correlation analyses. RESULTS: A total of 3150
pharmaceutical records from 301 CF patients were collected.
Annual and daily medication costs were analysed for different
age groups. Mean annual costs for medication are €21,603 per
patient (range: €69; €86,790). Correlation analyses showed sig-
niﬁcant correlations (p = 0.01) between costs of medication and
age, co-morbidities (like pancreatic insufﬁciency and diabetes
mellitus and clinical parameters like the colonization of the lung
with germs) as well as functional parameters (% of vital capacity,
FEV1, MEF25). E.g. mean annual costs for medication are
€14,884 (€23,815) for patients without (with) colonization of
the lung with germs. Other correlation factors yielded similar
cost dispersions in (un)affected patients. CONCLUSIONS:
CF patients need specialized medication depending on age,
co-morbidities and other clinical parameters. Non-optimal
treatment leads to signiﬁcantly higher costs for the health care
system.
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OBJECTIVES: Compare annual indirect costs between privately
insured employees with epilepsy and matched employee con-
trols. METHODS: Employees with greater than or equal to 1
epilepsy diagnosis (ICD-9-CM: 345.x) in 2004, ages 18–64
years, were selected from a privately insured claims database
containing disability data from 17 U.S. companies. A random
sample of age and gender matched employees without epilepsy
was selected as a control group. All were required to have con-
tinuous health coverage during 2004 (baseline) and 2005 (study
period). Chi-squared tests were used to compare baseline comor-
bidities and differences in indirect resource use (disability and
medically-related absenteeism). Wilcoxon rank-sum tests were
used for univariate comparisons of mean disability and
medically-related absenteeism days and associated annual indi-
rect costs during the study period. Two-part models were used to
compare indirect costs adjusting for differences in demographic/
clinical characteristics. RESULTS: Employees with epilepsy
(n = 1,866) averaged 48.4 years old (SD  10.4), and 55% were
male. Compared with controls, employees with epilepsy had
signiﬁcantly higher rates of mental disorders, substance abuse,
other neurological disorders and physical disorders measured by
the Charlson Comorbidity Index. Employees with epilepsy were
more likely to have a short- or long-term disability claim com-
pared with controls (16.5% vs 5.6%, respectively; P < 0.0001),
resulting in higher mean number of annual disability days (38.6
vs 6.6, respectively, P < 0.0001) and higher annual disability
costs ($1836 vs $338, respectively; P < 0.0001). Medically-
related absenteeism costs were also higher for employees with
epilepsy compared with controls ($1356 vs $904, respectively;
P < 0.0001). Average total indirect costs for employees with epi-
lepsy were $3912 vs $1242 for controls (P < 0.0001) and
remained signiﬁcantly higher after adjusting for patient charac-
teristics ($2793 vs $1578, respectively; P < 0.0001). CONCLU-
SIONS: Employees with epilepsy were three times more likely to
have disability workloss, had six times the number of disability
days, and three times higher indirect costs compared with
matched employee controls.
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OBJECTIVES: The objectives of this study were to estimate the
number of people with Alzheimer’s related morbidity and mor-
tality and to estimate the indirect costs for Alzheimer’s disease
in the United States. Alzheimer’s disease is a chronic progres-
sive disease with a prevalence rate of 10% of the United States
population at age 70 and a prevalence rate of 40% by age 90.
METHODS: The Human Capital method was used to estimate
indirect costs for Alzheimer’s disease. The Medical Expendi-
tures Panel Survey, a nationally representative database of U.S.,
non-institutionalized civilians was used to estimate the morbid-
ity (missed work and bed days) portion of indirect costs. The
value of a bed day was estimated at 40% of the daily wage rate
the person would have earned if they were in the workforce.
The 2004 National Vital Statistics Survey Mortality Data was
used to estimate the mortality portion of indirect costs for
Alzheimer’s disease. RESULTS: A total of 26,745,385 bed days
were reported by patients with Alzheimer’s in 2004. Of the
65,965 deaths that were reported due to Alzheimer’s, 8,320
occurred prior to life expectancy. In U.S. dollars the overall
total for indirect costs for Alzheimer’s patients in 2004 was
over $1.3 billion. The majority of indirect costs for people with
Alzheimer’s were due to morbidity. CONCLUSIONS: By the
year 2030, population estimates predict the most rapidly
growing population segment will be those 85 and older. Given
the increasing prevalence of Alzheimer’s disease with advancing
age, the number of persons developing Alzheimer’s disease will
increase dramatically over the next several decades as will the
indirect costs. This study most likely underestimates the mor-
bidity costs of Alzheimer’s disease because patients in nursing
homes and other institutions are not included in the Medical
Expenditures Panel Survey.
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OBJECTIVES: Our recent study has found that pharmacologi-
cal management of epilepsy within outpatient setting of Mon-
tenegro has been slightly different in comparison to developed
countries. This was probably the consequence of many medical
and non-medical inﬂuences, whose separate contribution to
prescribing cannot be fully explained. In this study we investi-
gated the one-year expenses for the outpatient pharmacological
management of epilepsy in our country, with particular high-
light on potential cost-saving. METHODS: Data about antiepi-
leptics (ATC code N03) which were prescribed for the
treatment of epilepsy (G40 code according to ICD-X revision)
during 2005 were extracted from the National database which
was set up within Republic Health Insurance Fund of Mon-
tenegro since 2003. Standard DDD/ATC (deﬁned daily dose/
anatomic-therapeutic-chemical) methodology for the outpatient
drug utilization was used. Than we multiplied the number of
prescribed DDDs per 1000 inhabitants per day (DTIDs) with
the average price of one DDD for each drug. Our country has
a population of approximately 660,000 people and currency is
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